Blood-Based Biomarkers for Alzheimer's Risk (p-tau217): Diagnostic Promise vs. Asymptomatic Screening Readiness

What is established

Phosphorylated tau at threonine 217 (p-tau217) is a fragment of the tau protein that becomes hyperphosphorylated in the presence of amyloid-beta pathology in the brain. It can now be measured in a standard blood draw using validated immunoassays, which is the practical breakthrough: for two decades, confirming amyloid pathology required either a lumbar puncture for cerebrospinal fluid analysis or an amyloid PET scan, both expensive, invasive or radiation-exposing, and poorly suited to repeat testing.

In 2025, the Alzheimer's Association published a formal clinical practice guideline on blood-based biomarkers, developed through a systematic review and GRADE evidence rating process. It concluded that these tests have matured enough to be used in the diagnostic workup of patients who present with objective cognitive impairment and are being evaluated by a memory-disorder specialist. That is a real, guideline-backed endorsement, but it is scoped narrowly to symptomatic patients inside specialist care, not to the general population.[2]

What the evidence for asymptomatic use actually shows

The strongest data on p-tau217 in people without cognitive symptoms comes from a secondary analysis combining the A4 trial (1,102 cognitively unimpaired older adults enrolled in an amyloid-targeting prevention trial) with the LEARN observational cohort (524 participants). Researchers tracked plasma p-tau217 over time and compared it against amyloid-PET imaging, the reference standard for detecting brain amyloid.[1]

The result was a strong predictive relationship: longitudinal p-tau217 measurements predicted amyloid-PET positivity with an area under the curve of roughly 0.87 to 0.89, which is a good discrimination statistic by any standard. This tells us the blood test tracks the same underlying biology that PET imaging detects, in people who have no memory or thinking symptoms at all.[1]

That is a meaningful scientific result, but it answers a narrower question than it might appear to. The study measured how well plasma p-tau217 predicts a brain scan finding, amyloid positivity. It did not measure, and was not designed to measure, how well the test predicts who will go on to develop cognitive decline, mild cognitive impairment, or dementia, or over what timeframe. The cohort was also 93.8% non-Hispanic White, which limits how confidently the accuracy figures generalize to other populations.[1]

The trap: a predicted scan finding is not a diagnosis, and a diagnosis is not a prognosis

What remains uncertain, and where the guidance draws the line

The Alzheimer's Association guideline is explicit and worth quoting in substance rather than in spirit: its recommendation is for use within the diagnostic workup of patients with objective cognitive impairment, evaluated by specialists in memory disorders. The guideline does not extend to screening asymptomatic, cognitively normal individuals in a general wellness or preventive-health setting, and it does not present blood-based biomarkers as a validated population screening tool.[2]

There is no null or negative trial among the evidence reviewed here, both sources are broadly supportive of the biology and the analytic performance of the test. The gap is not that the test performs poorly, it is that the population and outcome it has been validated against (amyloid-PET status in a research cohort) is not the same population and outcome relevant to a person asking a clinic to tell them their Alzheimer's risk. Longitudinal data connecting plasma p-tau217 trajectories to eventual clinical dementia in unselected, diverse populations, and data on what happens, psychologically and clinically, when asymptomatic people receive these results, are still being generated.[1][2]

What this means for you

This evidence supports keeping plasma p-tau217 out of routine, stand-alone screening panels offered to asymptomatic patients as a way to quantify Alzheimer's risk. The guideline itself does not support that use, and the strongest trial data available answers a different question than the one most patients are actually asking when they request an Alzheimer's blood test.

Where it does have a place is inside a physician-led workup for a patient who already has a documented cognitive concern, in the same category the guideline describes, as one input alongside cognitive testing and clinical judgment, not as a verdict delivered on its own. AION does not run fixed screening protocols and does not offer this test as a way to generate a definitive Alzheimer's risk number for people without symptoms. Any use of p-tau217 testing is decided case by case by the reviewing physician, with the limitations above discussed plainly before the test is ordered, not after the result arrives.